Novel drugs and therapeutic targets for severe mood disorders - PubMed (original) (raw)
Review
. 2008 Aug;33(9):2080-92.
doi: 10.1038/sj.npp.1301652. Epub 2008 Jan 2.
Affiliations
- PMID: 18172433
- DOI: 10.1038/sj.npp.1301652
Review
Novel drugs and therapeutic targets for severe mood disorders
Sanjay J Mathew et al. Neuropsychopharmacology. 2008 Aug.
Erratum in
- Neuropsychopharmacology. 2008 Aug;33(9):2300
Abstract
Monoaminergic-based drugs remain the primary focus of pharmaceutical industry drug discovery efforts for mood disorders, despite serious limitations regarding their ability to achieve remission. The quest for novel therapies for unipolar depression and bipolar disorder has generally centered on two complementary approaches: (1) understanding the presumed therapeutically relevant biochemical targets of currently available medications, and using that knowledge to design new drugs directed at both direct biochemical targets and downstream targets that are regulated by chronic drug administration; and (2) developing pathophysiological models of the illness to design therapeutics to attenuate or prevent those pathological processes. This review describes several promising drugs and drug targets for mood disorders using one or both of these approaches. Agents interacting with non-catecholamine neurotransmitter systems with particular promise for unipolar and bipolar depression include excitatory amino acid neurotransmitter modulators (eg, riluzole, N-methyl-D-aspartate antagonists, and AMPA receptor potentiators) and neuropeptide antagonists (targeting corticotropin releasing factor-1 and neurokinin receptors). Potential antidepressant and mood-stabilizing agents targeting common intracellular pathways of known monoaminergic agents and lithium/mood stabilizers are also reviewed, such as neurotrophic factors, extracellular receptor-coupled kinase (ERK) mitogen-activated protein (MAP) kinase and the bcl-2 family of proteins, and inhibitors of phosphodiesterase, glycogen synthase kinase-3, and protein kinase C. A major thrust of drug discovery in mood disorders will continue efforts to identify agents with rapid and sustained onsets of action (such as intravenous administration of ketamine), as well as identify drugs used routinely in non-psychiatric diseases for their antidepressant and mood-stabilizing properties.
Similar articles
- Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder.
Zarate CA Jr, Singh J, Manji HK. Zarate CA Jr, et al. Biol Psychiatry. 2006 Jun 1;59(11):1006-20. doi: 10.1016/j.biopsych.2005.10.021. Epub 2006 Feb 17. Biol Psychiatry. 2006. PMID: 16487491 Review. - Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, Chen G. Manji HK, et al. J Clin Psychiatry. 1999;60 Suppl 2:27-39; discussion 40-1, 113-6. J Clin Psychiatry. 1999. PMID: 10073385 Review. - Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
Gould TD, Manji HK. Gould TD, et al. Neuropsychopharmacology. 2005 Jul;30(7):1223-37. doi: 10.1038/sj.npp.1300731. Neuropsychopharmacology. 2005. PMID: 15827567 Review. - Intracellular signaling pathways pave roads to recovery for mood disorders.
Tanis KQ, Duman RS. Tanis KQ, et al. Ann Med. 2007;39(7):531-44. doi: 10.1080/07853890701483270. Ann Med. 2007. PMID: 17852035 Review. - Critical role of brain-derived neurotrophic factor in mood disorders.
Hashimoto K, Shimizu E, Iyo M. Hashimoto K, et al. Brain Res Brain Res Rev. 2004 May;45(2):104-14. doi: 10.1016/j.brainresrev.2004.02.003. Brain Res Brain Res Rev. 2004. PMID: 15145621 Review.
Cited by
- Ketamine for treatment-resistant unipolar depression: current evidence.
Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW. Mathew SJ, et al. CNS Drugs. 2012 Mar 1;26(3):189-204. doi: 10.2165/11599770-000000000-00000. CNS Drugs. 2012. PMID: 22303887 Free PMC article. Review. - Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ. de Bodinat C, et al. Nat Rev Drug Discov. 2010 Aug;9(8):628-42. doi: 10.1038/nrd3140. Epub 2010 Jun 25. Nat Rev Drug Discov. 2010. PMID: 20577266 Review. - Fetal alcohol spectrum disorders and abnormal neuronal plasticity.
Medina AE. Medina AE. Neuroscientist. 2011 Jun;17(3):274-87. doi: 10.1177/1073858410383336. Epub 2011 Mar 7. Neuroscientist. 2011. PMID: 21383101 Free PMC article. Review. - Target identification for CNS diseases by transcriptional profiling.
Altar CA, Vawter MP, Ginsberg SD. Altar CA, et al. Neuropsychopharmacology. 2009 Jan;34(1):18-54. doi: 10.1038/npp.2008.172. Epub 2008 Oct 15. Neuropsychopharmacology. 2009. PMID: 18923405 Free PMC article. Review. - Sigma receptors: potential targets for a new class of antidepressant drug.
Fishback JA, Robson MJ, Xu YT, Matsumoto RR. Fishback JA, et al. Pharmacol Ther. 2010 Sep;127(3):271-82. doi: 10.1016/j.pharmthera.2010.04.003. Epub 2010 May 11. Pharmacol Ther. 2010. PMID: 20438757 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous